【レポートの概要（一部）】
1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. An Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction to Dermatology
2.2.1 The Structure of Skin, Hair, and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.3.1 Acne: The Most Common Skin Disease
2.3.1.1 Acne: Epidemiology
2.3.1.2 Acne: Causes and Pathogenesis
2.3.1.3 Acne: Treatment
2.3.2 Dermatitis: Inflammation of the Skin
2.3.2.1 Atopic Dermatitis
2.3.2.2 Contact Dermatitis
2.3.2.3 Seborrhoeic Dermatitis
2.3.2.4 Nummular Dermatitis
2.3.2.5 Perioral Dermatitis
2.3.3 Psoriasis: A Complex Multi-factorial Disease
2.3.4 Rosacea: Vascular Instability
2.3.5 Alopecia: Excessive Shedding Of Hair
2.4 Skin Infections: A Serious Healthcare Threat
2.4.1 Bacterial Skin Infections
2.4.2 Fungal Skin Infections
2.4.3 Viral Skin Infections
2.5 Common Skin Treatments
2.5.1 Creams and Semisolid Emulsions
2.5.2 Ointments
2.5.3 Lotions
2.5.4 Solutions
2.5.5 Occlusive Therapy
2.5.6 Cleansing Agents
2.5.7 Powders and Hydrophilic Polymer
2.5.8 Anti-Infective Agents
2.5.9 Anti-Inflammatory Agents
2.6 Phases of Clinical Trials
2.7 Dermatological Drugs: Market Definition in this Report
3. The Global Dermatological Drugs Market, 2016-2026
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation of the Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market in 2015
3.4 The Global Dermatological Drugs Market: Market Forecast 2016-2026
3.5 Dermatological Drugs: Changing Market Shares by Sector 2016-2026
4. The Psoriasis Drugs Market: Market Analysis and Forecast 2016-2026
4.1 Psoriasis Treatments: The Dominance of Biologics
4.1.1 Leading Products in the Psoriasis Drugs Market, 2015
4.2 Psoriasis: Market Trends and Developments, 2016
4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
4.2.3 The Disadvantages of Biologics in Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2016-2026
4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2015-2026
4.4 Leading Drugs Used in the Treatment of Psoriasis
4.4.1 Humira (adalimumab) – AbbVie
4.4.1.1 Humira: Historical Sales Analysis, 2010-2015
4.4.1.2 Humira: Sales Forecast 2016-2026
4.4.1.3 Future Prospects for Biosimilar Versions of Humira
4.4.2 Stelara (ustekinumab) – Johnson & Johnson
4.4.2.1 Stelara: Historical Sales Analysis, 2010-2014
4.4.2.2 Stelara: Sales Forecast 2016-2026
4.4.2.3 Intensifying Competition for Stelara
4.4.3 Enbrel (etanercept) – Amgen/ Pfizer/ Takeda
4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
4.4.3.2 Enbrel: Historical Sales Analysis, 2008-2015
4.4.3.2 Enbrel: Patent Expiries and Potential Competition, 2016-2026
4.4.3.4 Enbrel: Sales Forecast 2016-2026
4.4.3.5 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
4.4.3.6 Competition from Other Drugs
4.4.3.7 Biosimilar Competition for Enbrel
4.4.4 Remicade (infliximab) – Johnson & Johnson
4.4.4.1 Remicade: Historical Sales Analysis, 2010-2015
4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2016-2026
4.4.4.3 Remicade: Sales Forecast 2016-2026
4.4.5 Taltz (ixekizumab) – Eli Lily
4.4.5.1 Taltz: Sales Forecast 2016-2026
4.4.6 Otezla (apremilast) – Celgene
4.4.6.1 Otezla: Sales Forecast 2016-2026
4.4.7 Cosentyx (secukinumab) – Novartis
4.4.7.1 Cosentyx: Sales Forecast 2016-2026
4.4.8 Other Psoriasis Drugs
4.4.8.1 Cimzia (certolizumab) – UCB
4.4.8.2 Sorilux (calcipotriene foam) – GSK
4.4.8.3 Other Psoriasis Drugs: Sales Forecast 2016-2026
4.5 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis and Forecast 2016-2026
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products in the Skin Infection Drugs Market, 2015
5.2 Skin Infection Drugs: Market Forecast 2016-2026
5.2.1 Skin Infection Drugs: Changing Market Shares by Leading Drugs 2016-2026
5.3 Leading Drugs Used in the Treatment of Skin Infections
5.3.1 Cubicin (daptomycin) – Cubist Pharmaceuticals/ Merck & Co
5.3.2 Acquisition By Merck & Co
5.3.3 Generic Competition For Cubicin
5.3.4 Cubicin: Sales Forecast 2016-2026
5.3.5 Lifecycle Management Strategies for Cubicin
5.4 Zyvox (linezolid) – Pfizer
5.4.1 Zyvox: Historical Sales Analysis, 2010-2014
5.4.2 Zyvox: Sales Forecast 2016-2026
5.4.3 The Threats to Zyvox Sales from Competing New Drugs
5.5 Canesten (clotrimazole) – Bayer
5.5.1 Canesten: Historical Sales Analysis, 2011-2014
5.5.2 Canesten: Sales Forecast 2016-2026
5.6 Valtrex (valaciclovir) – GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2014
5.6.2 Valtrex: Sales Forecast 2016-2026
5.7 Bactroban (mupirocin) – GSK
5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
5.7.2 Bactroban: Sales Forecast 2015-2026
5.8 Lamisil (terbinafine) – Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2016-2026
5.9 Other Skin Infection Drugs
5.9.1 Dalvance (dalbavancin) – Durata Therapeutics
5.9.2 Jublia (efinaconazole) – Valeant
5.9.3 Kerydin (tavaborole) – Anacor
5.9.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.9.5 Zovirax (acyclovir) – Valeant/GSK
5.9.5.1 Valeant Acquires Zovirax In US And Canada
5.9.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic
5.9.6 Other Skin Infection Drugs: Sales Forecast 2016-2025
5.10 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis and Forecast 2016-2026
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products in the Acne Drugs Market, 2015
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise of Combination Therapies in Acne Treatment
6.2.2 Oral Contraceptives in Treating Acne
6.2.3 The Threat of Generic Competition in the Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2015-2026
6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2015-2026
6.4 Leading Drugs in the Acne Drugs Market
6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.4.1.1 Epiduo: Sales Forecast 2016-2026
6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
6.4.1.3 Paediatric Approval for Epiduo
6.4.2 Solodyn (minocycline) – Valeant
6.4.2.1 Solodyn: Sales Forecast 2016-2026
6.4.2.2 Antitrust Action Over Solodyn Pay-For-Delay Deals
6.4.2.3 Impax And Medicis Collaborating On Advanced Solodyn
6.4.2.4 Medicis And Lupin Settle
6.4.3 Claravis (isotretinoin) – Teva
6.4.3.1 Claravis: Sales Forecast 2016-2026
6.4.4 Aczone (dapsone) – Allergan
6.4.4.1 Aczone: Sales Forecast 2016-2026
6.4.5 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.4.5.1 Recent Generic Competition to Differin
6.4.5.2 Differin: Sales Forecast 2016-2026
6.4.5.3 Adapalene Gel to be Available OTC in the US
6.4.5.4 Federal Circuit Court Invalidates Differin Patents
6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma
6.4.6.1 Absorica/Epuris: Sales Forecast 2016-2025
6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.4.7.1 Valeant’s Patent Settlement with Actavis Over Ziana
6.4.7.2 Ziana: Sales Forecast 2016-2026
6.4.8 Doryx (doxycycline) – Actavis/ Mayne Pharma
6.4.8.1 Lifecycle Management Strategies for Doryx
6.4.8.2 Divestment Agreement with Mayne Pharma
6.4.8.3 Generic Competition for Doryx
6.4.8.4 Doryx: Sales Forecast 2016-2026
6.4.9 Other Acne Drugs
6.4.9.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant
6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, And Watson
6.4.9.2 Amnesteem (isotretinoin) – Mylan
6.4.9.2.1 Amnesteem: Financial Analysis
6.4.9.3 Diane (cyproterone/ethinyl estradiol) – Bayer
6.4.9.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline
6.4.9.5 Veltin (tretinoin/clindamycin) – GSK
6.4.9.6 Other Acne Drugs: Sales Forecast 2016-2026
6.5 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis and Forecast 2016-2026
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products in the Dermatitis Drugs Market, 2015
7.2 Dermatitis Drugs: Market Forecast 2016-2026
7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2016-2026
7.3 Leading Drugs in the Dermatitis Drugs Market
7.3.1 Bepanthen (dexpanthenol)/ Bepanthol – Bayer
7.3.1.1 Bepanthen: Sales Forecast 2016-2026
7.3.2 Elocon (mometasone) – Merck & Co
7.3.2.1 Elocon: Sales Forecast 2016-2026
7.3.3 Protopic (tacrolimus) – LEO Pharma
7.3.3.1 Protopic Benefits from Expanded Indication
7.3.3.2 Generic Competition For Protopic
7.3.3.3 Protopic: Sales Forecast 2016-2026
7.3.4 Dermovate -GSK
7.3.4.1 Dermovate: Sales Forecast 2016-2026
7.3.5 Other Dermatitis Drugs: Sales Forecast 2016-2026
7.4 Dermatitis Drugs: Market Outlook
8. Leading National Markets for Dermatological Drugs, 2016-2026
8.1 The Dermatological Drugs Market by Region
8.1.1 The Global Distribution of Dermatological Drugs in 2015
8.2 Leading National Markets: Forecast 2016-2026
8.2.1 Changing Market Shares by Region, 2015-2026
8.3 Regional Dermatological Drugs Markets: Analysis and Forecasts, 2015-2026
8.3.1 United States: The Largest Dermatological Drugs Market
8.3.1.1 The Impact of an Expanding Medicare Coverage
8.3.1.2 Legislative Environment Stimulating Biosimilars Market?
8.3.1.3 US Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2 The EU5 Markets: Growth Expected in Each Country
8.3.2.1 EU5 Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2.1.1 EU5 Markets: Changing Market Shares by Country, 2015-2026
8.3.2.2 Germany
8.3.2.2.1 German Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2.3 France
8.3.2.3.1 French Dermatological Drugs Market Forecast 2016-2026
8.3.2.4 UK
8.3.2.4.1 UK Dermatological Drugs Market Forecast 2016-2026
8.3.2.5 Italy
8.3.2.5.1 Italian Dermatological Drugs Market Forecast 2016-2026
8.3.2.6 Spain
8.3.2.6.1 Spanish Dermatological Drugs Market Forecast 2016-2026
8.3.3 Japan
8.3.3.1 The Cost of Treatment in Japan
8.3.3.2 Japanese Pharmaceutical Industry Regulatory Reform
8.3.3.3 Japanese Dermatological Drugs Market Forecast 2016-2026
8.3.4 China
8.3.4.1 Expansion of Healthcare Coverage and Reimbursement in China
8.3.4.2 Improving Public Perception of Dermatology in China
8.4.3.3 Price Controls and the Anhui Model
8.3.4.4 Chinese Dermatological Drugs Market Forecast 2016-2026
8.3.5 India
8.3.5.1 The Effects of the Drug Prices Control Order of 2013
8.3.5.2 India’s Expansion of Healthcare Provision
8.3.5.3 Indian Dermatological Drugs Market Forecast 2016-2026
8.3.6 Brazil
8.3.6.1 The Growth in Brazil’s Healthcare Landscape
8.3.6.2 Clearer Access to Medicines in Brazil
8.3.6.3 Brazilian Dermatological Drugs Market Forecast 2016-2026
8.3.7 Russia
8.3.7.1 Pharma2020 Strategy – Healthcare and Industry Reform
8.3.7.2 Russian Dermatological Drugs Market Forecast 2016-2026
8.3.8 Rest of the World
8.3.8.1 The Rest of the World Dermatological Drugs Market Forecast 2016-2026
9. Leading Companies in the Dermatological Drugs Market, 2016-2026
9.1 Dermatological Drugs – A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2016
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestlé’s Acquisition of Galderma
9.2.2.2 Approval and Launch of Soolantra for Rosacea
9.3 Johnson & Johnson
9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015
9.3.2 Johnson & Johnson: Dermatological Drug Development
Pipeline, 2016
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2016
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2016
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2016
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2016
9.6.2 Pfizer: Dermatological Drugs Development Pipeline, 2016
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2016
9.7.2 LEO Pharma: Dermatological Drugs Development Pipeline, 2016
10. Dermatological Drugs: Research and Development Pipeline, 2016-2026
10.1 Innovative Products Currently in Development Will Drive Growth
10.1.1 New Technology in R&D Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms and Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2016
10.2.1 Psoriasis Drugs in Phase 3 Development or Regulatory Approval Stage
10.2.1.1 AMG 827 (brodalumab) – AstraZeneca/ LEO Pharma
10.2.1.2 CF101 (Piclidenoson) – Can-Fite BioPharma
10.2.1.3 CNTO 1959 (guselkumab) – MorphoSys/ Janssen
10.2.1.4 LAS41008 (dimethyl fumarate) – Almirall
10.2.1.5 MK-3222/SCH 900222 (tildrakizumab) – Merck/Sun Pharma
10.2.2 Psoriasis Drugs in Phase 2 Development
10.2.2.1 LY3009104 (baricitinib) – Incyte/ Eli Lilly
10.2.2.2 PH-10 (Rose Bengal) – Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2016
10.3.1 Drugs in Phase 3 Development for Skin Infections
10.3.1.1 Baxdela (delafloxacin) – Melinta Pharmaceuticals
10.3.1.2 NB-001 – NanoBio Corporation
10.3.1.3 Luliconazole – Topica Pharmaceuticals
10.3.2 Drugs in Phase 2 Development for Skin Infections
10.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
10.4 Acne Drugs Development Pipeline, 2016
10.4.1 Drugs in Phase 3 Development for Acne
10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) – GlaxoSmithKline
10.4.1.2 Visonac (photodynamic therapy) – Photocure
10.4.2 Drugs in Phase 2 Development for Acne
10.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
10.4.4 A Possible Vaccine for Acne
10.5 Dermatitis Drugs Development Pipeline, 2016
10.5.1 Drugs in Phase 3 Development for Dermatitis
10.5.1.1 Toctino (alitretinoin) – GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) – Regeneron/ Sanofi
10.5.2 Drugs in Phase 2 Development for Dermatitis
10.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2016
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) – Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) – Biofrontera
10.6.1.3 Mirvaso (brimonidine) – Galderma
10.6.1.4 Picato (ingenol mebutate) – LEO Pharma
10.6.1.5 Xolair (omalizumab) – Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2016
10.6.2.1 CD5024 (ivermectin) – Galderma
10.6.2.2 SR-T100 gel (Solanum incanum extract) – G&E Herbal Biotechnology
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2016
11. Qualitative Analysis of the Dermatological Drugs Market, 2016-2026
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis of the Global Dermatological Drugs Market, 2016-2026
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need in Dermatology
11.2.1.2 A Healthy Pipeline of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy and Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence – A Major Challenge to Treatment Design
11.2.2.3 Impending Patent Expiries and the Challenges Posed by Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors in Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances in Genomics
11.2.3.3 Advances in Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertain Surrounding Reimbursement and Payment Approvals
11.2.4.2 The Rising Cost of Research and Development
11.2.4.3 Downward Pressures on Drug Prices
11.3 Porter’s Five Force Analysis of the Global Dermatological Drugs Market, 2016-2026
11.3.1 Threat of New Entrants
11.3.2 Threat of Substitutes
11.3.3 Rivalry among Competitors
11.3.4 Power of Buyers
11.3.5 Power of Suppliers
12. Conclusions
12.1 Overview of Current Market Conditions and Market Forecast, 2015-2026
12.2 Leading Sectors in Dermatological Drugs in 2015
12.3 Leading Regions in the Dermatological Drugs Market in 2015
12.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2016-2026
12.5 What Does The Future Hold For Dermatological Drugs?
13. Glossary
【レポート販売概要】
■ タイトル：皮膚科治療薬の世界市場予測2016-2026■ 英文：Dermatological Drugs Market Forecast 2016-2026
■ 発行日：2016年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN81920
■ 調査対象地域：グローバル
- ナノセルロースの世界市場：バクテリアナノセルロース、ナノ結晶セルロース、マイクロフィビリル化セルロースAccording to Stratistics MRC, the global nanocellulose market is expected to grow at a CAGR of 19.5% by 2022. The factors driving the market include rising requirement for sustainable products with better material science and emerging inventive nanocellulose applications. An additional factor that contributes to the impressive growth of nanocellulose market is the ability and structure of nanocell …
- フェイシャルエステ（顔ケア）のグローバル市場2020Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets Summary GBI Research’s report, “Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets” discusses the market, competitive landscape, and trends for two facial aesthetics market segmen …
- ビックデータ分野のリーディング企業分析：Opera SolutionsBig Data represents a collection of data sets so large and complex that it becomes difficult to process using on-hand database management tool. It is also unstructured, meaning that it is not tabulated, correlated, etc. (e.g. it does not have a pre-defined data model or is not organized in a pre-defined manner). Big Data technologies enable organizations to handle huge datasets and generate inform …
- 炭酸エチレンの世界市場予測・分析2020-2024Global Ethylene Carbonate Market: About this market Technavio’s ethylene carbonate market analysis considers sales from lithium battery electrolyte, solvents, lubricants, photochromatic, and other applications. Our study also finds the sales of ethylene carbonate in APAC, Europe, MEA, North America, and South America. In 2019, the lithium battery electrolyte segment had a significant market share, …
- ヨーロッパ主要国の疼痛管理市場EU5 Pain Management Devices Market Outlook to 2021 Summary GlobalData’s new report, "EU5 Pain Management Devices Market Outlook to 2021", provides key market data on the EU5 Pain Management Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market. The report also provides company shares and distribution shares …
- アジアの電気生理処置機器市場見通し（～2021）Asia-Pacific Electrophysiology Procedures Outlook to 2021 Summary GlobalData’s new report, "Asia-Pacific Electrophysiology Procedures Outlook to 2021", provides key procedures data on the Asia-Pacific Electrophysiology Procedures. The report provides procedure volumes within market segment - Electrophysiology Ablation Procedures. The data in the report is derived from dynamic market forecast model …
- 世界の電子ペーパーディスプレイ市場（2014-2018）About e-Paper Display Electronic paper display or e-paper display is a portable, reusable electronic display medium, which has paper-like properties such as wide viewing angle, high flexibility, and no backlight. These displays reflect the incident light, thereby consuming less or no power to retain an image, but have low refresh rate. These displays are readable in direct sunlight, lightweight, a …
- 世界の製氷機市場2015The Global Ice Machine Industry Report 2015 is a professional and in-depth study on the current state of the Ice Machine industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Ice Machine market analysis is provided for the international markets including development trends, competitive landscape analysi …
- 子供用自転車の世界市場2016-2020About the Children’s Bicycle Market We expect the global children's bicycle market to grow at a CAGR of 2.31% during the forecast period. In 2015, APAC led the overall market for children's bicycles and was followed by Europe. The ROW, which is constituted of Latin America, the Middle East, and Africa, will see the fastest growth rate over the next five years. North America will register a slowdow …
- バイオベース・ポリウレタンの世界市場2016-2020About Bio-based Polyurethane Adipic acid, a petroleum-based compound, and few other di-acids are the commonly used conventional raw materials for manufacturing polyurethanes. However, natural oil polyols or bio-polyols derived from vegetable oils can also be used for manufacturing polyurethanes. These products are called bio-based polyurethanes. The most common sources of natural oil polyols inclu …
- ニューモシスチス・カリニ肺炎(Pneumocystis Carinii Pneumonia)：世界の治験レビュー2014年下半期版Pneumocystis Carinii Pneumonia Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Pneumocystis Carinii Pneumonia Global Clinical Trials Review, H2, 2014" provides data on the Pneumocystis Carinii Pneumonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pneumocystis Carinii Pneumonia. It includes an o …
- スモールセル及びWi-FiオフロードAs mobile data proliferates so too does the demand for capacity and coverage. Many options exist to cope with data surge. Small cell deployment and Wifi offloading are the main ones. Small cells give the opportunity to come closer to the user and to offer a better coverage, indoors or outdoors at low cost. Despite remaining technological hurdles, Wifi is a heavily deployed and cost-effective solut …
- コハク酸の世界市場予測（～2023年）“The succinic acid market is projected to register a CAGR of 6.8% between 2018 and 2023.”The global succinic acid market is estimated to be USD 132 million in 2018 and is projected to reach USD 183 million by 2023, at a CAGR of 6.8%. The increasing demand from the industrial, personal care and food & beverage industries fuels the succinic acid market. The increasing demand from the APAC region, an …
- 世界のシェールオイル（タイトオイル）における主要企業20社分析Leading oil and gas companies across the world continue to migrate their E&P capital expenditure budgets toward the now de-risked prospect of shale (tight) oil development in the US. By 2014, visiongain estimates that $68.2bn will be spent on shale (tight) oil development. The production of these assets produces an ever-more predictable return on investment and does not come with the political and …
- オプトエレクトロニクスの世界市場2017-2021：LED、光学アイソレータ、イメージセンサ、レーザダイオード、光スイッチAbout OptoelectronicsOptoelectronics is the study of combined technology of electronic device and light. It is a sub-field of photonics. The study includes visible light as well as X-rays, gamma rays, ultra-violet (UV) rays, and infrared (IR) rays. Optoelectronic devices act as optical-to-electrical or electrical-to-optical transducers. LED, image sensors, optical switches, laser diodes, and optic …
